A European life science VC fund manager that invests across all healthcare verticals and stages, in products with the potential to address unmet medical needs.

Hadean Ventures

Hadean Ventures is a European life science fund manager with a particular focus on the Nordic region. Hadean Ventures invests broadly across the life science sector, including in speciality pharmaceuticals, medical technology, diagnostics and digital health. Hadean Ventures has offices in Oslo and Stockholm.

Themis Bioscience

Galecto

Abliva AB

Our investment analyst Yun Yang, MD MSc had the chance to participate in a recent EIC ePitching event on MedTech and share her insight in an article. Thank you European Innovation Council and SMEs Executive Agency (EISMEA) for your continuous support in highlighting emerging MedTech companies in Europe.
#HadeanVentures #EISMEA #VentureCapital

Great day for our team event - kayaking on the Oslo-fjord enjoying the sunny weather and testing our skills! Happy summer 😊 #Hadeanventures #teambuilding #lifesciencevc

Great news from our portfolio company Attgeno, that successfully compleated their Phase II study for Supernitro. Congratulations! 
#Attgeno #HadeanVentures #VentureCapital

Thank you Tesi for letting us contribute to this article, and for being a great investor and partner for life science investments! 
#Tesi #HadeanVentures #lifescience #venturecapital

Hadean Ventures is pleased to announce that we have co-led a €63 million Series A financing round for SciRhom, a Munich-based Immunology & Inflammation (I&I) company. We were joined by co-lead investors Andera Partners, Kurma Partners, MIG Capital, and Wellington Partners, additional new investor Bayern Kapital, as well as existing investors.
 
Dr. Georgina Askeland, PhD, Senior Associate at Hadean Ventures, will join SciRhom’s Board of Directors.
 
“SciRhom has a unique approach that ticks all the boxes in I&I. In one stroke, their highly selective iRhom2 antibody targets a central pathway to cytokine release, shutting down multiple pathological inflammatory pathways while simultaneously promoting immune tolerance pathways. This could have transformative potential for patients with inflammatory and autoimmune diseases and we are excited to support the company to validate this clinically.”, says Dr. Georgina Askeland.

#HadeanVentures #SciRhom #VentureCapital #LifeScience

Good news! Hadean Ventures portfolio company Oncoinvent ASA receives FDA Fast Track Designation for lead candidate Radspherin!
#radiopharma #oncoinvent #hadeanventures #lifesciencevc 

https://lnkd.in/dEZgg8vD

HADE

COM:HADEANVENTURES

Hadean Ventures